EASD 2025 15 - 19 September 2025

REDEFINE 2: A randomised trial of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of adults with BMI ≥27 kg/m² and type 2 diabetes

Authors :

Melanie J Davies¹; Harpreet S Bajaj²; Christa Broholm³; Astrid Eliasen³; W Timothy Garvey⁴; Carel W le Roux⁵; Ildiko Lingvay⁶; Christian Bøge Lyndgaard³; Julio Rosenstock⁷; Lisa von Huth Smith³; Sue D Pedersen⁸

Affiliations

View Details Hide Details

Keywords

Obesity

Congress oral presentation

GLP-1 RA

CagriSema

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

REDEFINE 2: A randomised trial of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of adults with BMI ≥27 kg/m² and type 2 diabetes

Search Science Hub

Are you a healthcare professional?

REDEFINE 2: A randomised trial of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of adults with BMI ≥27 kg/m2 and type 2 diabetes

REDEFINE 2: A randomised trial of combined semaglutide 2.4 mg and cagrilintide 2.4 mg for the treatment of adults with BMI ≥27 kg/m² and type 2 diabetes